TB Alliance Names Maria Beumont as Vice President, Chief Medical Officer for Research and Development

Executive brings more than 20 years of experience in pharmaceutical development

February 2, 2022

NEW YORK (February 2, 2022)—TB Alliance today announced the appointment of Maria Beumont, MD to the position of Vice President, Chief Medical Officer for Research and Development. Dr. Beumont will develop and lead TB Alliance’s clinical strategy and provide oversight of clinical trial planning and execution of promising anti-tuberculosis drugs and regimens. Prior to joining TB Alliance, Dr. Beumont served as a Senior Medical Director at Janssen Pharmaceuticals, where she was involved in the development of treatments for hepatitis C and most recently held the role of Hepatitis Franchise Medical Lead.

“I am excited to join TB Alliance in its mission to develop better treatments for tuberculosis that are accessible to the millions who are impacted by this deadly infectious disease,” said Dr. Beumont. “I look forward to the opportunity to advance a pipeline of therapeutics that have the potential to significantly improve and shorten the TB treatment experience for patients.”

Dr. Beumont has had experience working in both the clinical application and public service sides of HIV treatment. Prior to joining Janssen, she was Medical Director at Chiron Corporation working on the application of immune response in the treatment of HIV, and she also served as the Director of HIV Services for the City of Philadelphia at the Philadelphia Department of Public Health. Dr. Beumont received her medical degree from the University of Buenos Aires, Argentina. She then moved to the United States where she completed a residency in Internal Medicine at Abington Memorial Hospital followed by a Fellowship in Infectious Diseases at the University of Pennsylvania.

“We are thrilled to have Dr. Beumont join TB Alliance,” said Dr. Mel Spigelman, President and CEO of TB Alliance. “As we advance the development and introduction of new TB therapies, her global experience and dedication to public health will contribute greatly to our vision of a TB-free world.”


About TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Foreign, Commonwealth and Development Office (United Kingdom), Cystic Fibrosis Foundation, Germany’s Federal Ministry of Education and Research through KfW, Global Disease Eradication Fund (Korea), Global Health Innovative Technology Fund, Indonesia Health Fund, Irish Aid, Korea International Cooperation Agency, Medical Research Council (United Kingdom), National Institute of Allergy and Infectious Diseases, Netherlands Ministry of Foreign Affairs, Republic of Korea’s Ministry of Foreign Affairs, and the United States Agency for International Development. For more information, visit www.tballiance.org.